BruceBMcCallMD

Oncology • South San Francisco, CA

Group Medical Director, Hematology/Oncology

Join to view full profile

Dr. McCall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCall's full profile

Already have an account?

Office
1 DNA Way
South San Francisco, CA 94080
Phone+1 415-846-8056

Education & Training

St Mary's Hospital and Medical CenterResidency, Internal Medicine, 2001 - 2004
University of WashingtonResidency, Anesthesiology, 1989 - 1993
University of California San Diego School of MedicineClass of 1989

Publications & Presentations

PubMed

100 citations
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor, Zhonglin Hao, Ramses F. Sadek, Robin Dobbins, Lisa Marshall
Journal for Immunotherapy of Cancer. 2018-06-20
39 citations
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorecta...
Andrew G. Hill, Michael Findlay, Matthew Burge, Christopher Jackson, Pilar García Alfonso
Clinical Cancer Research. 2018-05-15
32 citations
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carc...
Antonio Jimeno, Jean-Pascal Machiels, Lori J. Wirth, Pol Specenier, Tanguy Y. Seiwert
Cancer. 2016-12-15

Abstracts/Posters

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicit...
Bruce McCall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019